Your search for esrd returned 140 results

Intensive glucose therapy significantly reduces microalbuminuria and macroalbuminuria in adults with type 2 diabetes, but does not improve clinical renal outcomes.

Compromised kidneys significantly reduce survival and life expectancy in patients with systemic lupus erythematosus (SLE).

The labeling for Onglyza (saxagliptin; Bristol-Myers Squibb) has been updated to include data from two clinical trials: a study of Onglyza in patients with moderate to severe renal impairment or end-stage renal disease (ESRD) and a second comparator study of Onglyza + metformin versus glipizide + metformin.

Long-term daily use of fenofibrate is beneficial for patients with type 2 diabetes and moderate renal impairment and is not associated with an increase in drug-related safety concerns compared with those with mild renal impairment.

Keryx Biopharmaceuticals announced results from the Phase 2 study of Zerenex (ferric citrate) for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on thrice weekly hemodialysis.

Intradialytic hypotension is a common complication of hemodialysis and can lead to increased morbidity and mortality among patients with end-stage renal disease.

Screening not linked to improved patient survival after transplant; may delay time to listing, transplant

Few new end-stage renal disease (ESRD) patients are referred for kidney transplant evaluation within one year of starting treatment, although referral practices vary considerably.

End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.

In U.S. dialysis centers treating end-stage renal (ESRD) patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, vancomycin is overprescribed, despite evidence of lower rates of hospitalization and death in cefazolin-treated patients.